Sodium Bicarbonate Administration in Out-of-Hospital Cardiac Arrest

Sodium Bicarbonate Administration in Patients Undergoing Ongoing Cardiopulmonary Resuscitation for Refractory Out-of-Hospital Cardiac Arrest with Severe Metabolic Acidosis and Excessive Base Deficit at Hospital Arrival: A Double-Blind, Randomized, Placebo-Controlled Pilot Study (BASE-OHCA trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0010655

Enrollment

138

Registered

2025-06-20

Start date

2025-08-04

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The study includes non-traumatic out-of-hospital cardiac arrest patients who, within 10 minutes of arrival at the emergency department, are confirmed by arterial blood gas analysis to have a pH

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients must meet all of the following conditions: ? Adult out-of-hospital cardiac arrest (OHCA) patients aged 19 years or older and under 80 years, presenting to the emergency department. ? Patients with non-traumatic cardiac arrest. ? Arterial blood gas analysis performed immediately upon arrival at the emergency department shows pH = 7.0 and base excess = -10.

Exclusion criteria

Exclusion criteria: 1. Cases in which respiratory acidosis is suspected based on arterial blood gas analysis results. 2. Cases in which cardiac arrest is clearly suspected to have been caused by hyperkalemia or where sodium bicarbonate is clearly indicated (e.g., tricyclic antidepressant overdose). 3. Arterial blood gas analysis is delayed more than 10 minutes after emergency department arrival. 4. Patients who are receiving extracorporeal membrane oxygenation. 5. Patients with poor pre-arrest neurological status, defined as Cerebral Performance Category 3 or 4. 6. Patients who have agreed to a DNR (Do Not Resuscitate) order or have refused ICU admission or mechanical ventilation, thereby limiting treatment. 7. Patients with terminal underlying diseases (e.g., metastatic end-stage cancer) where active treatment is not planned or survival to discharge is not expected. 8. Patients or their legally authorized representatives who do not voluntarily consent to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Sustained recovery of spontaneous circulation more than 20 minutes	—

Secondary

Measure	Time frame
Changes in pH in Serial Arterial Blood Gas Analysis;Survival to admission;Neuron specific enolase at 48 hours after recovery of spontaneous circulation;Mortality rate at 30 days;Time to death (90 day);In-hospital Mortality Rate (%);Early Mortality Rate Within 7 Days;Mortality rate at 90 days;Cerebral Performance Category score at discharge ;Cerebral Performance Category score at 30 days;Cerebral Performance Category score at 90 days;Time to Awakening (day)	—

Measure

Time frame

Changes in pH in Serial Arterial Blood Gas Analysis;Survival to admission;Neuron specific enolase at 48 hours after recovery of spontaneous circulation;Mortality rate at 30 days;Time to death (90 day);In-hospital Mortality Rate (%);Early Mortality Rate Within 7 Days;Mortality rate at 90 days;Cerebral Performance Category score at discharge ;Cerebral Performance Category score at 30 days;Cerebral Performance Category score at 90 days;Time to Awakening (day)

—

Countries

Korea, Republic of

Contacts

Public ContactYoun-Jung Kim

Asan Medical Center

yjkim.em@gmail.com+82-2-3010-0329

Outcome results